]>
IRCT20090117001556N111 IRCT 2018-07-25 Tehran University of Medical Sciences saffron for attention deficit hyperactivity disorder in adults Saffron (crocus sativus) for attention deficit hyperactivity disorder in adults: a double blind and placebo controlled trial 2018-08-05 anticipated 40 Complete https://irct.ir/trial/32813 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random Permuted block, Blinding description: The participants, clinicians and outcome evaluators will be blind regarding grouping. 3 Disturbance of activity and attention. Intervention 1: Intervention group: Capsule saffron 15 mg BID plus Tab. ritaline ( methylphenidate) 30 mg per day for 6 weeks. Intervention 2: Control group: Capsule placebo plus tab. ritaline ( methylphenidate) 30 mg per day. Yes - There is a plan to make this available What will be shared: All data will be distributed through final report When: from 2021 to 2026 To whom: En academic researchers Conditions: All users should cite the source of data Where to obtain: prof Shahin Akhondzadeh How to obtain: by E mail Comments:
public Prof. Shahin Akhondzadeh
Roozbeh Hospital, South Kargar Street,
Tehran Iran (Islamic Republic of) 1333715914 +98 21 5541 2222 s.akhond@sina.tums.ac.ir Tehran University of Medical Sciences scientific Shahin Akhondzadeh
Roozbeh Hospital, South Kargar Street
Tehran Iran (Islamic Republic of) 1333715914 +98 21 5541 9113 s.akhond@sina.tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) Diagnosis of ADHD based on DSM-5 Age between 20-60 years old 20 years 60 years Both Chronic medical disease including seizure, cardiovascular disease, CVA and organic brain disease Substance abuse or dependence during past six months Nursing or pregnant patients History of tic disorder Receiving of any psychotropics drugs during past two weeks, Intellectual disability History of suicide attempt, psychosis or aggressiveness Receiving psycho-stimulants or atomoxetine during past three months Bipolar disorder F90 Attention-deficit hyperactivity disorders Treatment - Drugs Placebo Intervention group: Capsule saffron 15 mg BID plus Tab. ritaline ( methylphenidate) 30 mg per day for 6 weeks Control group: Capsule placebo plus tab. ritaline ( methylphenidate) 30 mg per day Severity of ADHD. Timepoint: Baseline (before treatment) and weeks: 3 and 6 after treatment. Method of measurement: By adult ADHD Self-Report Scale and Conners Adult ADHD Rating Scales–Self-Report-screening version. Tehran University of Medical Sciences Approved 2018-07-14 Ethics Committee of Tehran University of Medical Sciences Tehran University of Medical Sciences, Qhods St., Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)